Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bioptik Technology Incorporation (4161:TWSE), powered by AI.
Bioptik Technology Incorporation is currently trading at $22.95. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Bioptik Technology Incorporation on Alpha Lenz.
View Bioptik Technology Incorporation's valuation metrics on Alpha Lenz.
“Bioptik Technology Incorporation's ROE is 7.6%. Explore profitability and growth together.”
Ask for details →Bioptik Technology Incorporation is a healthcare technology company specializing in the development, manufacture, and distribution of medical devices and diagnostics, as well as beauty and health products. Founded in 1999 and headquartered in Taiwan, the company is notable for its advanced blood glucose, cholesterol, and uric acid monitoring systems—which it markets under the EasyMate and Easy Touch brands—aimed at both clinical and home-use segments. Bioptik Technology also produces testing strips for these systems and offers a robust line of hyaluronic acid-based skincare and cosmetic products, distributed under the ACUREAL label. In addition to its healthcare focus, the company is involved in health supplements and has research efforts in bioenergy and biotechnology, reflecting a commitment to continuous innovation. Bioptik’s products are distributed across domestic and international markets, serving healthcare providers, laboratories, and consumers. The company positions itself as a pillar of innovation in the Taiwanese medical technology sector, emphasizing in-house R&D, quality assurance, and customer satisfaction in its pursuit of improving health monitoring and personal wellness.
“Bioptik Technology Incorporation's ROE is 7.6%. Explore profitability and growth together.”
Ask for details →Bioptik Technology Incorporation (ticker: 4161) is a company listed on TWSE in the Healthcare sector (Medical Devices).
The current price is 22.95 with a P/E ratio of -x and P/B of -x.
ROE is 7.61% and operating margin is 7.95%. Annual revenue is $837M.